---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040950"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:40:30.575566+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology Q2 2023: Net loss $32.2M; cash $512.1M; pipeline advances with Phase 3 start

## Summary
- Cash and investments $512.1M as of June 30, 2023; expected runway into 2026.
- Net loss $32.2M in Q2 2023 vs $58.1M in Q1 2023; R&D expenses decreased due to one-time $25M upfront in Q1.
- Phase 3 REZILIENT-3 study of zipalertinib in EGFR exon20 NSCLC first-line initiated in August 2023.
- CLN-619 monotherapy expansion cohorts in endometrial and cervical cancers initiated; first patient dosed in Phase 1 CLN-978 for R/R B-NHL.
- IND cleared for CLN-617; Phase 1 study expected to start in H2 2023.

## SEC filing metadata
- accession: 0000950170-23-040950
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/0000950170-23-040950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/cgem-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040950
- JSON: https://secwatch.observer/filing/0000950170-23-040950.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040950.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017023040950/0000950170-23-040950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.